Skip to main content
HQY logo

HQY · Healthequity, Inc.

Track HQY — free
$104.22 +0.76 (+0.73%)
Market Cap
$8.56B
Shares
82.72M
Volume · Nov 16 234.01K Avg daily vol (3M) 867.78K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$103.46 Open$103.88 Day$102.58–104.01 52W close$73.21–108.84 Avg vol 30d795K Short int5.5M · 6.6% of shares · 7.6d Short vol44% Last earningsAug 27, 2026 DataJan 2020–Nov 2026 Filing10-Q · Aug 27

Up next

Dec 1, 2026 Announced · in 2 wks
Dec 1, 2026 Scheduled · in 2 wks

Latest documents

2026
Oct 9
Current report 8-K Events of Oct 5
Director or officer change, or executive pay

HealthEquity, Inc. terminated Michael Fiore as Chief Commercial Officer without cause, effective October 5, 2026, and will redistribute his responsibilities among other members of its management team.

Aug 27
Quarterly report 10-Q FY2027 Q2, ended Jul 31
Quarterly report for FY2027 Q2 AI summary on its way
Revenue $350.73M ▲ 7.6% Net income $65.64M ▲ 9.7% Diluted EPS $0.78 ▲ 14.7%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.36B
Trailing 12 months
Net income (TTM)
$236.49M
Trailing 12 months
Revenue growth YoY
+7.6%
Year over year
Operating margin
25.8%
Trailing 12 months
P / E (TTM)
37.4
Trailing earnings · reciprocal yield 2.7%
FCF yield
5.7%
TTM · current market cap
Return on invested capital
10.1%
Trailing 12 months
Net cash
−$675.06M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-4.3%
Year over year · fewer shares
Price change (1Y)
+4.0%
Trailing year
Short interest
6.6%
Latest settlement · 7.6 days to cover
View all 125 metrics

AI Brief

Q2 FY27 earnings call · Aug 27, 2026
Q2 FY27

TL;DR. Q2 delivered higher revenue, net income, and adjusted EBITDA, a record adjusted EBITDA margin, strong HSA growth, and raised fiscal 2027 guidance. Operational efficiencies reduced calls, while the company generated operating cash flow and repurchased stock; risks include CDB product shifts, service-price erosion, a $3.3 million disposal expense, immaterial Marketplace revenue, competition, and cybersecurity exposure.

Bullish
  • + Q2 revenue increased 8%, net income increased 10%, adjusted EBITDA increased 11%, and adjusted EBITDA margin rose to 48% from 46%.
  • + Management raised fiscal 2027 revenue guidance to $1.411 billion-$1.421 billion and adjusted EBITDA guidance to $628 million-$636 million.
  • + Total HSA assets increased 14% year over year to $37.9 billion.
  • + HSAs increased 8% year over year to 10.7 million, while HSAs with investments increased 20% to 0.9 million.
  • + Operational efficiencies reduced human-handled calls 25% year over year and card-related calls 30%.
  • + The company generated $136 million of operating cash flow and repurchased approximately $108 million of stock during the quarter.
Bearish
  • − Some clients are shifting from other CDB products, particularly FSA, toward greater HSA adoption.
  • − Headline price erosion is a headwind to year-over-year service revenue growth.
  • − Q2 results included a $3.3 million one-time disposal expense for unused internally developed software.
  • − Marketplace revenue remains immaterial to overall financial results.
  • − HealthEquity faces significant competition, including competitors with greater resources.
  • − Potential cybersecurity breaches could cause costs, liabilities, reputational damage, and loss of business.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +15%
above
Price vs 50-day avg +8%
above
RSI (14) 58
neutral
MACD trend Negative
52-week position 85%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +12%
trailing
6-month return +19%
trailing
YTD return +13%
this year
Relative strength +18%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $96 › 200d $90 — 50d above 200d
Institutional flow Accumulating
458 of 506 funds reported for Sep 30 · net +1.1M sh shares · +62 new
Insider flow Distributing
Net -$1.6K over 90 days · 50% sells
Short interest Falling
6.62% of shares out · ▼ -7.9% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
506 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Excellent
Revenue growth +29%
Y/Y
Gross margin 398%
contracting
EPS growth +126%
Y/Y
Free cash flow $455.1M
Valuation P/E 37.4
below peers
Buyback $948.4M
remaining
Balance sheet $638.5M
net debt
Quant / Vol
risk profile
Moderate
Volatility 35%
annualized · 1-yr
Max drawdown −31%
past year
ATR 3.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the Earnings Call filed Aug 27, 2026
Revenue · fiscal 2027 Maintained $1.41B – $1.42B
May 28, 2026 $1.41B – $1.42B changed to Aug 27, 2026 $1.41B – $1.42B
prior FY $1.31B midpoint +7.8% Y/Y
Gap net income ... per share · fiscal 2027 $2.88 – $2.96
prior FY $2.46 midpoint +18.7% Y/Y
Gap net income · fiscal 2027 $242M – $248M
Non-gap net income · fiscal 2027 $392M – $398M
Non-gap net income per share · fiscal 2027 $4.66 – $4.73
Average yield on HSA cash · fiscal 2027 Raised 3.85% – 3.9%
May 28, 2026 3.85% changed to Aug 27, 2026 3.85% – 3.9%
Adjusted EBITDA · fiscal 2027 Raised $628M – $636M
May 28, 2026 $625M – $633M changed to Aug 27, 2026 $628M – $636M
Non-GAAP income tax rate · fiscal 2027 25%
GAAP income tax rate · fiscal 2027 25%
Prior guidance period ended · from the 8-K filed Dec 3, 2025
Revenues · fiscal year ending January 31, 2026 $1.3B – $1.31B
Net income · fiscal year ending January 31, 2026 $197M – $205M
Non-GAAP net income · fiscal year ending January 31, 2026 $341M – $348M
Net income per diluted share · fiscal year ending January 31, 2026 $2.24 – $2.33
Non-GAAP net income per diluted share · fiscal year ending January 31, 2026 $3.87 – $3.95
Adjusted EBITDA · fiscal year ending January 31, 2026 $555M – $565M
Guided vs delivered · last 8 settled
Revenues fiscal year ending January 31, 2026
guided $1.3B – $1.31B
$1.31B Beat +0.5%
Net income per diluted share fiscal year ending January 31, 2026
guided $2.24 – $2.33
$2.46 Beat +7.7%
Revenues fiscal year ending January 31, 2025
guided $1.14B – $1.16B
$1.2B Beat +4.3%
Net income per diluted share fiscal year ending January 31, 2025
guided $0.83 – $0.99
$1.09 Beat +19.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+15% Bullish
Price vs 50-day avg
+8% Bullish
RSI (14)
58 Neutral
MACD trend
Negative Bearish
52-week position
85% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $96 › 200d $90 — 50d above 200d
Institutional flow Accumulating
458 of 506 funds reported for Sep 30 · net +1.1M sh shares · +62 new
Insider flow Distributing
Net -$1.6K over 90 days · 50% sells
Short interest Falling
6.62% of shares out · ▼ -7.9% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
506 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $73 Now $103 · 85% Range high $109
vs 200-day avg +15% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Average daily Client-held funds - Quarter-to-date 936M July 31, 2026 —
Average daily Client-held funds - Year-to-date 986M July 31, 2026 —
Average daily HSA cash - Quarter-to-date 17.39B July 31, 2026 —
Average daily HSA cash - Year-to-date 17.55B July 31, 2026 —
Average Total Accounts - Quarter-to-date 17.71M July 31, 2026 —
Average Total Accounts - Year-to-date 17.77M July 31, 2026 —
CDBs 7.02M July 31, 2026 —
Client-held funds $0.9B as of July 31, 2026 —
HSA cash $17.4B as of July 31, 2026 —
HSA investments $20.6B as of July 31, 2026 —
HSAs 10.7M as of July 31, 2026 —
HSAs with investments 0.9M as of July 31, 2026 —
New HSAs from sales 202K second quarter ended July 31, 2026 —
New HSAs from sales - Quarter-to-date 202K July 31, 2026 —
New HSAs from sales - Year-to-date 374K July 31, 2026 —
Remaining stock repurchase authorization $948.4M as of July 31, 2026 —
Shares repurchased 1.2M second quarter ended July 31, 2026 —
Stock repurchases $108.1M second quarter ended July 31, 2026 —
Total Accounts 17.8M as of July 31, 2026 —
Total HSA Assets $37.9B as of July 31, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HQY
Healthequity, Inc.
this stock
$8.56B +12.9% +28.7% 37.4 6.6%
VEEV
Veeva Systems Inc
$48.82B +35.1% +28.1% 49.4 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$14.17B +90.1% +28.2% 38.7 5.8%
TEM
Tempus AI, Inc.
$13.06B +21.3% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
537
% held
109.8%
Reported
458 of 506
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
558
View
Short & Settlement
Short Interest Falling
Shares short
5.5M
Days to cover
7.6d
Change
-469.2K sh
View
Short Volume
Short vol %
44%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$113.4K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
41.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.6K
Buyers / Sellers
1 / 1
Buyers Sellers
View
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Jul 10, 2026
View
Financials
Financials
Revenue (FY)
$1.3B
Net income (FY)
$215.2M
EPS diluted
$2.46
View
Buybacks
Remaining
$948.4M
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 9, 2026
This year
17

HealthEquity, Inc. terminated Michael Fiore as Chief Commercial Officer without cause, effective October 5, 2026, and will redistribute his responsibilities among other members of its management team.

View
Proposed Sales
Value
$185.2K
Shares
2.0K
Filed
Oct 8, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Aug 27, 2026
View
Investor Relations
Latest news
HealthEquity Schedules Third Quar…
Published
Nov 3, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
HQY -0.2% +12.4% +18.6% +1.0% +12.9%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -2.8% +13.6% +18.1% +1.2% +2.3%

Capital returns

Buyback program · as of Jul 31, 2026
Authorized
—
Spent (derived)
—
Remaining
$948.40M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1428336 CUSIP 42226A107 13F (30d) 418 filings 380 filers Visit website Investor relations